Navigation Links
Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer

e cancer is the most common form of cancer among men. The incidence is strongly age-related and is unusual before age 50. In 2006, 2.2 million new cases were estimated to have been diagnosed in the US alone.

Lund, March 9, 2007

Active Biotech AB (publ) Sven Andréasson President and CEO

For further information, please contact: Sven Andréasson, President and CEO, tel. +46 46 19 20 49 Tomas Leanderson, Chief Scientific Officer, tel +46 46 19 20 95 Cecilia Hofvander, Manager Corporate Communication, tel. +46 46 19 11 22

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB (org.nr 556223-9227) P.O. Box 724, SE-220 07 Lund, Sweden Tel +46 46-19 20 00 Fax +46 46-19 20 50


'"/>




Page: 1 2

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

Post Your Comments:
(Date:11/6/2009)... MURRYSVILLE, Pa., Nov. 6 Philips ...r Disease Control and Prevention (CDC) to raise aw...chronic sleep insufficiency. The CDC,s release of ...y-state differences in sleeplessness is a mileston.... ,, As a long-time educator, industry leader ...
(Date:11/6/2009)... NEW YORK, Nov. 6 Keryx ...d a conference call on Tuesday, November 10, 2009 ... financial results and business outlook for the re...icer of the Company, will host the call. Keryx wi...in a press release to be issued prior to the call....
(Date:11/6/2009)... ATLANTA, Nov. 6 GeoVax...or "the Company"), an Atlanta-based, biopharmaceut...s caused by HIV-1 (Human Immunodeficiency Virus) a...ird quarter 2009 financial results and provided an...President and Chief Executive Officer commented, "...
Breaking Medicine Technology:Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Discovery May Pave Way to Better Diabetes Care 56967 1Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference 14004 1Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference 14004 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 1Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 2Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 3Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 4Phase 3 Trial of Aflibercept in Metastatic Pancreatic Cancer Discontinued 4975 5
...bled Time to Progression and Overall Response Rate...bine + Placebo in Patients with 2nd or 3rd Line Me... Biopharmaceuticals, Inc. (Nasdaq: KERX ) today ...1 (perifosine), the Company,s Akt-inhibitor for ca...ent for advanced colon cancer. Abstract #4081, en...
...SCO Meeting , , INDIANAPOLIS, May 30 Semafore Ph...discovery and development company, today presented...r targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, at...SCO) Annual Meeting, being held in Orlando, Florid...a University Simon Cancer Center in Indianapolis,...
Other Medicine Technology:Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients 2Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients 3
(Date:11/8/2009)..., WASHINGTON, Nov. 7 To...k, Pitts, Kaptur, Dahlkemper, Smith, Ellsworth and... for America Act" (H.R. 3962). The amendment maint...ing for abortion and for benefits packages that in...h those who receive affordability credits and thos...
(Date:11/8/2009)..., Calls for Swift Passage of H.R. 3961 to Secure ...PRNewswire-USNewswire/ -- Statement Attributable t...cal Association. ,, (Logo: http://www.newscom...AMA hails the passage of the House health reform b... patients and physicians and calls for swift passa...
(Date:11/8/2009)..., HOLLYWOOD, Calif., Nov. 8 /PRNewswire-USNewswire...ration of Babies luncheon to recognize prominent i...children and who are role models for March of Dime...part of the March of Dimes November Prematurity Aw...ests were urged to join the fight for preemies! ,...
(Date:11/7/2009)..., Jacquelyn T. Coleman (CT), David A. Cook (GA), ... L. Tarver (LA) Honored ,, CHICAGO, Nov. 7 /PR...iation (AMA) today presented five medical society ... their contributions to the goals and ideals of th... the AMA,s semi-annual policy making meeting in Ho...
(Date:11/7/2009)..., WASHINGTON, Nov. 7 Th...se of Representatives to vote for the Stupak-Ellsw...he Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipins...ral law on abortion funding and conscience protect... (H.R. 3962)," they said. ,, The letter was sig...
Breaking Medicine News(10 mins):Health News:Family Research Council Praises Passage of Pro-life Amendment to Health Care Bill 2Health News:AMA Hails House Passage of Health Reform Bill (H.R. 3962) 2Health News:Hollywood Stars Joined in a Celebration of Babies 2Health News:Hollywood Stars Joined in a Celebration of Babies 3Health News:AMA Honors Medical Society Executives 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
...hether they may benefit from more,intensive screen...AVIK, Iceland, Oct. 8 deCODE genetics,(Nasdaq: D...ancer(TM), a new,tool for assessing risk of the co...erstand her lifetime risk of developing,the common...
...inations are now being,accepted for The 2009 Dr. P...ecognizes scientists in basic or clinical research...butions toward the improvement of human,health. No...he winner(s) will be announced in May 2009., Inst...
...unch of TransForce(R)2 Arch Developer ...ct. 8 Ortho Organizers, Inc., a,leading global ma...vices,and continuing education programs, announced...pansion,appliance are available; Transverse, for e...
...llowing statement was,issued today by HealthMadeEa...ons that is a major contributing factor to a very ...ity of healthcare, reducing access and,dramaticall...culty is directly related to the overall shortage ...
...renterologist Dr. Patricia Raymond offers tips on ... East Longmeadow, MA (PRWEB) October 8, 2008 -...t, the average person passes gas about 14 times pe...e one of those unlucky few, follow these recommend...
...Skin & Laser Center is well established as a t... New York City. The facility is living up to its r...est skin resurfacing treatments to receive FDA app...treatment industry is in the midst of an unprecede...
Other Medicine News:Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 2Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 3Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 4Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 5Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 6Health News:deCODE Launches deCODE BreastCancer(TM), a Genetic Test to Screen for Risk of the Common Forms of Breast Cancer 7Health News:2009 Nominations Open for The Dr. Paul Janssen Award for Biomedical Research 2Health News:2009 Nominations Open for The Dr. Paul Janssen Award for Biomedical Research 3Health News:The Next Generation of Arch Expansion has Arrived 2Health News:HealthMadeEasy.com: Our Healthcare System Is Hemorrhaging 2Health News:HealthMadeEasy.com: Our Healthcare System Is Hemorrhaging 3Health News:Managing Gas Isn't Rocket Science 2Health News:Managing Gas Isn't Rocket Science 3Health News:Upscale New York City Skin Care Center Juva Offering FDA Approved Fraxel re:fine System 2
... peels are often thought of as very aggressive and...l™ TCA peels are very different from the sta...h many ingredients including lactic acid, ascorbic...c and azelaic acids to produce dramatic results wi...
...ating rapid exfoliator. Lactic Acid is is recommen... agents in skin care products, as well as those th...nd want to improve results. ,Lactic Acid is a natu...h the chemical free style of Peel RX Medi Peel pro...
Specialist's Skin Peel Kit
Glycolic Peels (Medical)
Medicine Products: